Novel genes in primary aldosteronism

Current Opinion in Endocrinology, Diabetes and Obesity

Volumn 21, Issue 3, 2014, Pages 154-158

  Fischer, Evelyn ^a   Beuschlein, Felix ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

adrenal adenoma; ATP1A1; ATP2B3; CACNA1D; exome sequencing; KCNJ5; primary aldosteronism; somatic mutations

Indexed keywords

ADENOSINE TRIPHOSPHATASE; ALDOSTERONE; POTASSIUM CHANNEL; ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM); ATP1A1 PROTEIN, HUMAN; CALCIUM CHANNEL L TYPE; G PROTEIN COUPLED INWARDLY RECTIFYING POTASSIUM CHANNEL; KCNJ5 PROTEIN, HUMAN;

ALDOSTERONE RELEASE; CLINICAL FEATURE; EXOME; GENE MUTATION; GENE SEQUENCE; GENETIC PROCEDURES; GENETIC VARIABILITY; GERMLINE MUTATION; GLOMERULOSA CELL; HUMAN; HYPERTENSION; NEUROMUSCULAR DISEASE; POINT MUTATION; PREVALENCE; PRIMARY HYPERALDOSTERONISM; REVIEW; SEIZURE; SEX DIFFERENCE; STEROIDOGENESIS; ADRENAL CORTEX ADENOMA; ADRENAL CORTEX TUMOR; FEMALE; GENETIC PREDISPOSITION; GENETICS; HYPERALDOSTERONISM; MALE; METABOLISM; MUTATION; SECRETION (PROCESS);

ADRENAL CORTEX NEOPLASMS; ADRENOCORTICAL ADENOMA; ALDOSTERONE; CALCIUM CHANNELS, L-TYPE; FEMALE; G PROTEIN-COUPLED INWARDLY-RECTIFYING POTASSIUM CHANNELS; GENETIC PREDISPOSITION TO DISEASE; HUMANS; HYPERALDOSTERONISM; MALE; MUTATION; SODIUM-POTASSIUM-EXCHANGING ATPASE;

EID: 84899902682     PISSN: 1752296X     EISSN: 17522978     Source Type: Journal    
DOI: 10.1097/MED.0000000000000060     Document Type: Review

References (31)

1. Mulatero P, Stowasser M, Loh KC, et al. Increased diagnosis of primary aldosteronism, including surgically correctable forms, in centers from five continents. J Clin Endocrinol Metab 2004; 89:1045-1050.
2. Eide IK, Torjesen PA, Drolsum A, et al. Low-renin status in therapy-resistant hypertension: a clue to efficient treatment. J Hypertens 2004; 22:2217-2226.
3. Hannemann A, Bidlingmaier M, Friedrich N, et al. Screening for primary aldosteronism in hypertensive subjects: results from two German epidemiological studies. Eur J Endocrinol 2012; 167:7-15.
4. Reincke M, Fischer E, Gerum S, et al. Observational study mortality in treated primary aldosteronism: the German Conn's registry. Hypertension 2012; 60:618-624.
5. Catena C, Colussi G, Nadalini E, et al. Cardiovascular outcomes in patients with primary aldosteronism after treatment. Arch Intern Med 2008; 168:80-85.
6. Milliez P, Girerd X, Plouin PF, et al. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol 2005; 45:1243-1248.
7. Reincke M, Meisinger C, Holle R, et al. Is primary aldosteronism associated with diabetes mellitus? Results of the German Conn's registry. Horm Metab Res 2010; 42:435-439.
8. Funder JW, Carey RM, Fardella C, et al. Case detection, diagnosis, and treatment of patients with primary aldosteronism: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2008; 93:3266-3281.
9. Lifton RP, Dluhy RG, Powers M, et al. A chimaeric 11 beta-hydroxylase/ aldosterone synthase gene causes glucocorticoid-remediable aldosteronism and human hypertension. Nature 1992; 355:262-265.
10. Choi M, Scholl UI, Yue P, et al. K+ channel mutations in adrenal aldosteroneproducing adenomas and hereditary hypertension. Science 2011; 331:768-772.
11. Beuschlein F, Boulkroun S, Osswald A, et al. Somatic mutations in ATP1A1 and ATP2B3 lead to aldosterone-producing adenomas and secondary hypertension. Nat Genet 2013; 45:440-444; 444e1-2.
12. Scholl UI, Nelson-Williams C, Yue P, et al. Hypertension with or without adrenal hyperplasia due to different inherited mutations in the potassium channel KCNJ5. Proc Natl Acad Sci U S A 2012; 109:2533-2538.
13. Mulatero P, Tauber P, Zennaro MC, et al. KCNJ5 mutations in European families with nonglucocorticoid remediable familial hyperaldosteronism. Hypertension 2012; 59:235-240.
14. Boulkroun S, Beuschlein F, Rossi GP, et al. Prevalence, clinical, and molecular correlates of KCNJ5 mutations in primary aldosteronism. Hypertension 2012; 59:592-598.
15. Akerstrom T, Crona J, Verdugo AD, et al. Comprehensive re-sequencing of adrenal aldosterone producing lesions reveal three somatic mutations near the KCNJ5 potassium channel selectivity filter. PLoS One 2012; 7:e41926.
16. Azizan EA, Lam BY, Newhouse SJ, et al. Microarray, qPCR, and KCNJ5 sequencing of aldosterone-producing adenomas reveal differences in genotype and phenotype between zona glomerulosa- and zona fasciculatalike tumors. J Clin Endocrinol Metab 2012; 97:E819-E829.
17. Funder JW. The genetics of primary aldosteronism: chapter two. Hypertension 2012; 59:537-538.
18. Azizan EA, Poulsen H, Tuluc P, et al. Somatic mutations in ATP1A1 and CACNA1D underlie a common subtype of adrenal hypertension. Nat Genet 2013; 45:1055-1060.
19. Taguchi R, Yamada M, Nakajima Y, et al. Expression and mutations of KCNJ5 mRNA in Japanese patients with aldosterone-producing adenomas. J Clin Endocrinol Metab 2012; 97:1311-1319.
20. Xekouki P, Hatch MM, Lin L, et al. KCNJ5 mutations in the National Institutes of Health cohort of patients with primary hyperaldosteronism: an infrequent genetic cause of Conn's syndrome. Endocr Relat Cancer 2012; 19:255-260.
21. Oki K, Plonczynski MW, Luis Lam M, et al. Potassium channel mutant KCNJ5 T158A expression in HAC-15 cells increases aldosterone synthesis. Endocrinology 2012; 153:1774-1782.
22. Beuschlein F. Regulation of aldosterone secretion: from physiology to disease. Eur J Endocrinol 2013; 168:R85-R93.
23. Scholl UI, Goh G, Stölting G, et al. Somatic and germline CACNA1D calcium channel mutations in aldosterone-producing adenomas and primary aldosteronism. Nat Genet 2013; 45:1050-1054.
24. Morth JP, Pedersen BP, Toustrup-Jensen MS, et al. Crystal structure of the sodium-potassium pump. Nature 2007; 450:1043-1049.
25. 2+ ATPase of animal cells: structure, function and regulation. Arch Biochem Biophys 2008; 476:65-74.
26. Seccia TM, Mantero F, Letizia C, et al. Somatic mutations in the KCNJ5 gene raise the lateralization index: implications for the diagnosis of primary aldosteronism by adrenal vein sampling. J Clin Endocrinol Metab 2012; 97:E2307-E2313.
27. Oßwald A, Fischer E, Degenhart C, et al. Lack of influence of somatic mutations on steroid gradients of adrenal vein sampling in aldosterone producing adenomas. Eur J Endocrinol 2013; 169:657-663.
28. Mazzocchi G, Neri G, Rucinski M, et al. Ghrelin enhances the growth of cultured human adrenal zona glomerulosa cells by exerting MAPKmediated proliferogenic and antiapoptotic effects. Peptides 2004; 25: 1269-1277.
29. Shigematsu K, Nishida N, Sakai H, et al. Primary aldosteronism with aldosterone-producing adenoma consisting of pure zona glomerulosa-type cells in a pregnant woman. Endocr Pathol 2009; 20:66-72.
30. Spat A, Hunyady L. Control of aldosterone secretion: a model for convergence in cellular signaling pathways. Physiol Rev 2004; 84:489-539.
31. Brown MJ, Hopper RV. Calcium-channel blockade can mask the diagnosis of Conn's syndrome. Postgrad Med J 1999; 75:235-236.